Learn More
FR4 Monoclonal Antibody (eBioTH6), Functional Grade, eBioscience™, Invitrogen™
Rat Monoclonal Antibody
Brand: Affymetrix eBioscience 16-5446-85
244.01 GBP valid until 2024-03-29
Use promo code "21615" to get your promotional price.
Code : Z2
Additional Details : Weight : 0.01000kg
Description
Description: The monoclonal antibody eBioTh6 recognizes FR4, also known as FR delta and FBP3 (folate binding protein3). FR4 is a heavily glycosylated 35 kD receptor for folic acid and the physiologic circulating form of the vitamin, N5-methyltetrahydrofolate. Natural T regs have high levels of FR4 and together with CD25 can be used to distinguish natural Tregs, effector T cells, memory-like T cells and naive T cells. In vivo studies with eBioTH6 show a decrease in the number of CD4+CD25+ cells and an enhanced tumor response leading to the elimination of advanced stages of tumors. Based on co-staining studies, the epitopes recognized by eBioTH6 and eBio12A5 (cat 51-5445) are different thereby allowing functional studies with TH6 to be evaluated with eBio12A5. Applications Reported: This eBioTH6 antibody has been reported for use in flow cytometric analysis, immunoprecipitation and in vivo depletion. Applications Tested: This eBioTH6 antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Endotoxin: Less than 0.001 ng/ug antibody as determined by the LAL assay.
FR4 is a heavily glycosylated 35 kD receptor for folic acid and the physiologic circulating form of the vitamin, N5-methyltetrahydrofolate. Natural T regs have high levels of FR4 and together with CD25 can be used to distinguish natural Tregs, effector T cells, memory-like T cells and naive T cells. In vivo studies with eBioTH6 show a decrease in the number of CD4+CD25+ cells and an enhanced tumor response leading to the elimination of advanced stages of tumors.Specifications
FR4 | |
Monoclonal | |
1 mg/mL | |
PBS with no preservative; pH 7.2 | |
Q9EQF4 | |
Izumo1r | |
Affinity chromatography | |
RUO | |
64931 | |
4° C | |
Liquid |
Flow Cytometry, Functional Assay, Immunoprecipitation | |
eBioTH6 | |
Functional Grade | |
Izumo1r | |
0910001L11Rik; C86255; Folate receptor 4; folate receptor 4 (delta); folate receptor 4 (delta) homolog; folate receptor 4, delta (putative); folate receptor delta; Folate-binding protein 3; Folbp3; Folr4; FR-delta; IZUMO1 receptor protein JUNO; IZUMO1 receptor, JUNO; Izumo1r; Juno; probable folate receptor delta; sperm-egg fusion protein Juno | |
Rat | |
500 μg | |
Primary | |
Mouse | |
Antibody | |
IgG2b κ |
For Research Use Only.